PURPOSE: Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing cells. In phase I studies, brentuximab vedotin demonstrated significant activity with a favorable safety profile in patients with relapsed or refractory CD30-positive lymphomas. PATIENTS AND METHODS: In this multinational, open-label, phase II study, the efficacy and safety of brentuximab vedotin were evaluated in patients with relapsed or refractory Hodgkin's lymphoma (HL) after autologous stem-cell transplantation (auto-SCT). Patients had histologically documented CD30-positive HL by central pathology review. A total of 102 patients were treated with brentuximab vedotin 1.8 mg/kg by intravenous infusion every 3 weeks. In the absence of disease progression or prohibitive toxicity, patients received a maximum of 16 cycles. The primary end point was the overall objective response rate (ORR) determined by an independent radiology review facility. RESULTS: The ORR was 75% with complete remission (CR) in 34% of patients. The median progression-free survival time for all patients was 5.6 months, and the median duration of response for those in CR was 20.5 months. After a median observation time of more than 1.5 years, 31 patients were alive and free of documented progressive disease. The most common treatment-related adverse events were peripheral sensory neuropathy, nausea, fatigue, neutropenia, and diarrhea. CONCLUSION: The ADC brentuximab vedotin was associated with manageable toxicity and induced objective responses in 75% of patients with relapsed or refractory HL after auto-SCT. Durable CRs approaching 2 years were observed, supporting study in earlier lines of therapy.
PURPOSE: Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing cells. In phase I studies, brentuximab vedotin demonstrated significant activity with a favorable safety profile in patients with relapsed or refractory CD30-positive lymphomas. PATIENTS AND METHODS: In this multinational, open-label, phase II study, the efficacy and safety of brentuximab vedotin were evaluated in patients with relapsed or refractory Hodgkin's lymphoma (HL) after autologous stem-cell transplantation (auto-SCT). Patients had histologically documented CD30-positive HL by central pathology review. A total of 102 patients were treated with brentuximab vedotin 1.8 mg/kg by intravenous infusion every 3 weeks. In the absence of disease progression or prohibitive toxicity, patients received a maximum of 16 cycles. The primary end point was the overall objective response rate (ORR) determined by an independent radiology review facility. RESULTS: The ORR was 75% with complete remission (CR) in 34% of patients. The median progression-free survival time for all patients was 5.6 months, and the median duration of response for those in CR was 20.5 months. After a median observation time of more than 1.5 years, 31 patients were alive and free of documented progressive disease. The most common treatment-related adverse events were peripheral sensory neuropathy, nausea, fatigue, neutropenia, and diarrhea. CONCLUSION: The ADC brentuximab vedotin was associated with manageable toxicity and induced objective responses in 75% of patients with relapsed or refractory HL after auto-SCT. Durable CRs approaching 2 years were observed, supporting study in earlier lines of therapy.
Authors: A Sureda; M Constans; A Iriondo; R Arranz; M D Caballero; M J Vidal; J Petit; A López; J J Lahuerta; E Carreras; J García-Conde; J García-Laraña; R Cabrera; I Jarque; D Carrera; J C García-Ruiz; M J Pascual; J Rifón; J M Moraleda; K Pérez-Equiza; C Albó; J Díaz-Mediavilla; A Torres; P Torres; J Besalduch; J Marín; M V Mateos; J M Fernández-Rañada; J Sierra; E Conde Journal: Ann Oncol Date: 2005-02-28 Impact factor: 32.976
Authors: Anas Younes; Nancy L Bartlett; John P Leonard; Dana A Kennedy; Carmel M Lynch; Eric L Sievers; Andres Forero-Torres Journal: N Engl J Med Date: 2010-11-04 Impact factor: 91.245
Authors: Robert Chen; Joycelynne M Palmer; Leslie Popplewell; Jessica Shen; Eileen Smith; Maria Delioukina; Neil Kogut; Joseph Rosenthal; Stephen Forman; Auayporn Nademanee Journal: Ann Hematol Date: 2011-01-06 Impact factor: 3.673
Authors: Joseph A Francisco; Charles G Cerveny; Damon L Meyer; Bruce J Mixan; Kerry Klussman; Dana F Chace; Starr X Rejniak; Kristine A Gordon; Ron DeBlanc; Brian E Toki; Che-Leung Law; Svetlana O Doronina; Clay B Siegall; Peter D Senter; Alan F Wahl Journal: Blood Date: 2003-04-24 Impact factor: 22.113
Authors: Volker Diehl; Jeremy Franklin; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Dirk Hasenclever; Hans Tesch; Richard Herrmann; Bernd Dörken; Hans-Konrad Müller-Hermelink; Eckhardt Dühmke; Markus Loeffler Journal: N Engl J Med Date: 2003-06-12 Impact factor: 91.245
Authors: Nancy L Bartlett; Alex F Herrera; Eva Domingo-Domenech; Amitkumar Mehta; Andres Forero-Torres; Ramon Garcia-Sanz; Philippe Armand; Sumana Devata; Antonia Rodriguez Izquierdo; Izidore S Lossos; Craig Reeder; Taimur Sher; Robert Chen; Sylvia E Schwarz; Leila Alland; Andras Strassz; Kim Prier; Cassandra Choe-Juliak; Stephen M Ansell Journal: Blood Date: 2020-11-19 Impact factor: 22.113
Authors: Kenneth R Carson; Scott D Newsome; Ellen J Kim; Nina D Wagner-Johnston; Gloria von Geldern; Craig H Moskowitz; Alison J Moskowitz; Alain H Rook; Pankaj Jalan; Alison W Loren; Daniel Landsburg; Thomas Coyne; Donald Tsai; Dennis W Raisch; LeAnn B Norris; P Brandon Bookstaver; Oliver Sartor; Charles L Bennett Journal: Cancer Date: 2014-04-25 Impact factor: 6.860
Authors: Wei Wei; Yuquan Lin; Zhihui Song; Wenming Xiao; Liqi Chen; Jiejing Yin; Yan Zhou; Stefan K Barta; Michael Petrus; Thomas A Waldmann; Yibin Yang Journal: Clin Cancer Res Date: 2020-04-16 Impact factor: 12.531